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Abstract
Introduction Patients with cirrhosis are at risk for adverse drug reactions (ADRs) due to altered pharmacokinetics and phar-
macodynamics. We aimed to determine the prevalence of drug prescriptions and the potential safety of these prescriptions 
in a real-world cohort of patients with cirrhosis.
Methods This was a retrospective cohort study based on linked real-world data from the Out-patient Pharmacy Database 
and the Hospitalisation Database of the PHARMO Database Network. Patients with a diagnosis of cirrhosis between January 
1998 and December 2015 were included. Follow-up ended when the patient underwent a liver transplant, died, transferred 
out of the database, or on 31 December 2015. Prescription data were derived from a community pharmacy database and 
were compared with our previously developed safety recommendations for 209 drugs.
Results In total, 5618 patients were included and followed for a median of 3 years (interquartile range [IQR] 1–7). In the first 
year after the diagnosis, patients used a median of nine drugs (IQR 5–14), with proton pump inhibitors (prevalence 53.9%), 
aldosterone antagonists (43.6%), and sulfonamide diuretics (41.3%) being the most commonly used drug groups. Almost 
half (48.3%) of 102,927 prescriptions consisted of drugs with a safety recommendation. The prevalence of potentially unsafe 
drug use was 60.0% during the total follow-up. Three nonsteroidal anti-inflammatory drugs (NSAIDs) were among the five 
most commonly used potentially unsafe drugs.
Conclusions Patients with cirrhosis use a large number of drugs. Almost two-thirds of patients in our cohort used potentially 
unsafe drugs. To prevent ADRs in these frail patients, personalised pharmacotherapy is necessary.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-018-0744-1) contains 
supplementary material, which is available to authorized users.
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Key Points 
Patients with cirrhosis have an increased risk of adverse 
drug reactions due to pharmacokinetic and pharmaco-
dynamic changes, and the large number of medications 
they use.
Potentially unsafe drug use is common in patients with 
cirrhosis and more efforts are needed to decrease the use 
of these drugs in these patients.
Clinical decision support can be used to alert healthcare 
professionals when prescribing potentially unsafe drugs 
in patients with cirrhosis.
1 Introduction
Worldwide, approximately 1 million people die every year of 
liver cirrhosis [1]. Cirrhosis develops due to persistent liver 
damage caused by chronic liver diseases. Patients usually 
require several medications for the treatment of their disease 
and its complications, but few studies assessed drug utiliza-
tion in cirrhotic patients [2–4]. Almost 30% of patients with 
cirrhosis suffer from adverse drug reactions (ADRs) [2]. The 
risk of ADRs is exacerbated as a result of hepatic impair-
ment influencing drug pharmacokinetics and pharmacody-
namics [5, 6]. For example, exposure to pantoprazole is five- 
to eightfold increased in patients with cirrhosis compared 
with healthy controls due to decreased hepatic clearance 
[7, 8]. Likewise, the use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) increases the risk for renal impairment [9, 
10]. Patients with cirrhosis therefore require personalised 
pharmacotherapy.
Recently, we published practical guidance for over 
200 drugs to support healthcare professionals in prescrib-
ing drugs to patients with cirrhosis [11]. To prioritize the 
remaining drugs to be evaluated and to explore potential 
improvements for safe prescribing in these patients, current 
drug use needs to be mapped. An evaluation of prescribing 
in cirrhosis was the subject of two previous studies [12, 13], 
both of which were hospital-based, cross-sectional studies 
that compared prescriptions with data from the product label 
and a combination of literature. There is limited knowledge 
on real-world drug use in primary care, where the risks may 
be higher due to a wider range of drugs prescribed with less-
intensive monitoring. Therefore, the aims of our study were 
to (1) determine which drugs are most frequently used in a 
real-world cohort of patients with cirrhosis, and (2) compare 
real-world drug use with our previously elaborated practical 
guidance on safe drug use in cirrhosis [11].
2  Methods
2.1  Study Type and Data Source
This was a retrospective cohort study based on linked data 
from the Out-patient Pharmacy Database and the Hospitali-
sation Database of the PHARMO Database Network [14]. 
This population-based network of healthcare databases com-
bines data from different primary and secondary healthcare 
settings. The Out-patient Pharmacy Database contains data 
on general practitioner- and specialist-prescribed healthcare 
products, dispensed by community pharmacies, while the 
Hospitalisation Database comprises information on hospital 
admissions, including diagnoses of hospital discharges, from 
the national Dutch Hospital Data Foundation [15]. Together, 
these databases cover an area of almost 4 million residents 
of The Netherlands, representative of the total population 
of The Netherlands.
2.2  Study Population
The Hospitalisation Database was used to include patients 
with a diagnosis of cirrhosis between January 1998 and 
December 2015. They were selected by International Clas-
sification of Diseases, Ninth Revision (ICD-9) codes 571.2 
or 571.5, and, after 2013, by ICD Tenth Revision (ICD-10) 
codes K70.3 or K74.6. The index date was the date of dis-
charge from hospital with a diagnosis of cirrhosis. Patients 
younger than 18 years of age at the index date, and patients 
with a liver transplant before the index date, were excluded. 
Patients who did not receive a single drug dispensing after 
the index date were also excluded as they were probably 
lost to follow-up. Follow-up was ended when the patient 
underwent a liver transplant (ICD-9 code V42.7, ICD-10 
code Z94.4), transferred out of the database because of 
death or another reason, or on 31 December 2015, which-
ever occurred first. From the included patients, all dispensed 
drugs during the total follow-up were extracted from the 
Out-patient Pharmacy Database. Available data from the 
Hospitalisation Database were the ICD coding of cirrho-
sis per patient, his or her date of discharge with the diag-
nosis of cirrhosis, and, if applicable, the date of a liver 
transplantation.
2.3  Analyses
To determine the most frequently used drugs, we calculated 
the period prevalence of drug use in the first year of fol-
low-up and during the total follow-up. For this, we divided 
the number of drug users per period by the total number 
of patients during that period. Drugs were categorized into 
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subgroups according to the Anatomical Therapeutic Chemi-
cal (ATC) classification system (4th level) [16]. ATC sub-
groups were counted only once per patient. We listed the 10 
most frequently used ATC subgroups and their main indi-
vidual drugs (ATC 5th level). Of these 10 most frequently 
used subgroups, the period prevalence per calendar year 
from 1998 to 2015 was also determined. For every calendar 
year, the number of users per subgroup was divided by the 
total number of patients in the database in that year.
The potential safety of drug use was assessed using the 
practical guidance we recently published on safe prescribing 
for 209 drugs in patients with cirrhosis [11]. In this guid-
ance, every drug was classified according to potential safety 
risks (i.e. safe, no additional risks known, additional risks 
known, unsafe, and unknown), and, if applicable, specific 
dosing advice was also given. For some medications, the 
safety class depends on the severity of cirrhosis (Child–Pugh 
class [17]). Since no data were available in the database 
regarding the severity of cirrhosis, these drugs could not 
be classified further. Drugs not included in the practical 
guidance were classified as ‘safety not yet evaluated’. Per 
safety class, the period prevalence of drug use during the 
total follow-up was determined. We also listed the five most 
frequently used drugs per safety class. Because no data on 
clinical outcomes were available, we only assessed ‘potential 
safety’ of drug use.
Descriptive statistics were used to describe the character-
istics of the study population. All analyses were performed 
using Statistical Package for the Social Sciences (SPSS) 
version 24 (IBM Corporation, Armonk, NY, USA), and 
the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) statement was used to report 
this study.
3  Results
3.1  Patient Characteristics
In total, 5618 patients with cirrhosis were included (Fig. 1). 
Characteristics of the study population are shown in Table 1. 
Males represented 59.4% of patients and the mean age was 
60.7 years (SD 12.5). Almost half of the patients (49.5%) 
suffered from alcoholic cirrhosis, while the cause of cirrho-
sis was different or unspecified in 50.5% of patients.
3.2  Characteristics of Prescriptions
In total, there were 102,927 prescriptions written during 
the total follow-up. In the first year of follow-up, patients 
used a median of nine different drugs (interquartile range 
[IQR] 5–14). Analysing the duration of use, 37.6% of drugs 
were dispensed only once, 15.2% were administered twice, 
and the remaining (47.2%) were administered more often 
(median 2; IQR 1–7). General practitioners wrote 61.5% of 
prescriptions, specialists wrote 36.4% of prescriptions, and 
for 2.2% of prescriptions, the prescriber was either another 
healthcare professional or was unknown.
Table 2 shows the most frequently used drug groups dur-
ing the total follow-up, with their main individual drugs. 
Proton pump inhibitors and diuretics were most often used. 
The period prevalence of use of these drug groups was also 
determined per calendar year from 1998 to 2015 (see elec-
tronic supplementary material Fig. 1). Period prevalence 
of most groups slightly decreased over time, while usage 
of proton pump inhibitors steadily increased from approxi-
mately 30% in 1998 to almost 40% in 2015.
3.3  Assessment of Potential Safety
Of the 102,927 prescriptions, 48.3% consisted of one of the 
209 drugs that carried a safety recommendation accord-
ing to [11], while the safety of the remaining prescriptions 
(51.7%) has not yet been evaluated. During the total follow-
up, almost all patients used at least one drug for which safety 
has not yet been evaluated (96.4%) (Table 3). Furthermore, 
almost 40% (39.9%) of patients used a drug for which the 
limited clinical data do not allow safety to be determined 
(‘unknown’). More than two-thirds (68.9%) of patients used 
a drug for which safety depends on the severity of cirrhosis 
(Child–Pugh class [17]).
Potentially unsafe drugs were used by 60.0% of patients 
during the entire follow-up. Most patients used one of these 
drug (35.7% of patients), but 24.3% used multiple drugs 
(range 2–8). Examining the duration of use, 63.3% of poten-
tially unsafe drugs were dispensed more than once (median 
Fig. 1  Study inclusion process
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2; IQR 1–8). General practitioners prescribed 62.6% of 
potentially unsafe drugs, specialists prescribed 33.3%, and 
the prescriber was either another healthcare professional or 
was unknown in 4.2% of prescriptions. Pantoprazole was the 
most commonly used potentially unsafe drug, while three 
NSAIDs were in the top five (Table 3).
4  Discussion
This study described drug utilization in a large, real-world 
cohort of patients with cirrhosis. We demonstrated that 
patients with cirrhosis used a median of nine drugs in the 
year after the diagnosis, with proton pump inhibitors and 
diuretics being the most commonly used drug groups. Nearly 
half of the prescriptions consisted of drugs with a safety 
advice, and the potential safety of these prescriptions were 
further assessed. Almost two-thirds of patients used a poten-
tially unsafe drug during the study period, while 40% used a 
drug for which safety was never clinically studied in patients 
with cirrhosis.
Two hospital-based studies examined drug utilization in 
cirrhosis on a smaller scale. The first was a Spanish mul-
ticentre prospective study in a cohort of a little over 500 
admitted patients [3, 4], while the second was a retrospective 
chart study in a Swiss university hospital among 400 patients 
[2, 13]. We found a comparable prevalence of drug use for 
complications of cirrhosis (i.e. diuretics, β-blockers and 
osmotically acting laxatives); however, the use of NSAIDs, 
benzodiazepines and glucocorticoids seemed higher in our 
cohort. A possible explanation for this is that the largest part 
of prescriptions in our study came from general practition-
ers, i.e. primary care. In addition, the proportion of proton 
pump inhibitor use appeared higher in our study, which is 
probably due to the increasing prevalence of proton pump 
inhibitor use found over time [18, 19].
We found a period prevalence of 60% potentially unsafe 
drug use during the total follow-up. As we only assessed 
potential safety for half of the prescriptions, potentially 
unsafe drug use is possibly more prevalent. NSAIDs were 
frequently prescribed, however they increase the risk of 
renal dysfunction and gastrointestinal bleeding in patients 
with cirrhosis and therefore should be avoided [11, 13]. 
Healthcare professionals are often not aware of these risks 
and are afraid of prescribing paracetamol because of pos-
sible hepatotoxicity [20, 21]. The prevalence of diclofenac 
use was indeed higher than paracetamol use in our study. 
While paracetamol does cause hepatotoxicity when over-
dosing, conversion to the reactive hepatotoxic metabolite 
is not increased in cirrhosis but possibly even decreased 
due to reduced enzyme activity [22]. Research is limited 
in decompensated patients with other risk factors for hepa-
totoxicity (malnourishment or chronic alcohol abuse) and 
a dose reduction may be warranted [22]. Pantoprazole and 
atorvastatin are potentially unsafe drugs also commonly 
used. For both drugs, large pharmacokinetic alterations 
occur in patients with cirrhosis (five- to sevenfold increases 
in exposure [8, 23]), and in our practical guidance we there-
fore recommended using another drug from the same group 
without these large increases in exposure (e.g. esomepra-
zole or rosuvastatin) in order to prevent ADRs [7, 24, 25]. 
Almost 40% of patients used a drug classified as ‘unknown’, 
Table 1  Characteristics of the study population
Data are expressed as n (%) unless otherwise specified
Unique drug prescriptions were the number of different individual drugs prescribed (ATC 5th level)
IQR interquartile range, SD standard deviation, ATC Anatomical Therapeutic Chemical
Total Alcoholic cirrhosis Other or 
unspecified 
cirrhosis
No. of patients 5618 (100.0) 2782 (100.0) 2836 (100.0)
Sex
 Male 3339 (59.4) 1810 (65.1) 1529 (53.9)
 Female 2279 (40.6) 972 (34.9) 1307 (46.1)
Age, years [mean ± SD] 60.7 ± 12.5 58.4 ± 10.5 62.9 ± 13.9
Years of follow-up [median (IQR)] 3 (1–7) 4 (1–8) 3 (1–7)
Reason for end of follow-up
 Liver transplantation 179 (3.2) 56 (2.0) 123 (4.3)
 31 December 2015 3278 (58.3) 1650 (59.3) 1628 (57.4)
 Other (died or transferred out of the database) 2161 (38.5) 1076 (38.7) 1085 (38.3)
Unique drug prescriptions in the first year of follow-up [median (IQR)] 9 (5–14) 8 (5–12) 9 (5–14)
Unique drug prescriptions during total follow-up [median (IQR)] 28 (18–43) 26 (16–39) 31 (20–46)
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meaning there was no, or not enough, literature to formu-
late a recommendation on safety and dosing in cirrhosis. 
Most prevalent in this class were some important antibiotics 
(i.e. doxycycline, nitrofurantoin and flucloxacillin). Clinical 
research is needed to assess the safety of these drugs in cir-
rhosis. Likewise, almost all patients used a drug for which 
no safety evaluation was yet available. Based on the findings 
of this study, prioritization of the subsequent drugs to be 
evaluated is possible. Benzodiazepines are important can-
didates based on their high prevalence of use.
Patients in this study were followed for several years to 
get a complete picture of real-world drug use. We excluded 
cirrhotic patients without a single drug prescription during 
the total follow-up as these were most likely patients lost to 
follow-up, either because they moved away or they received 
their drugs from a pharmacy outside the database area, and, 
in some cases, mislinkage may have occurred. Excluding 
these patients might have resulted in an overestimation of 
the prevalence of drug use; however, we think it was unlikely 
that patients with cirrhosis did not receive any medication 
after hospital discharge and during total follow-up.
Our cohort included a substantial number of cirrhotic 
patients in The Netherlands. We did not have detailed clini-
cal data, which limited our analyses. A comparison with 
the prescribed dose was therefore not possible because most 
dosing recommendations depend on the severity of cirrhosis 
(Child–Pugh class [17]). Likewise, information on the out-
come of treatment (i.e. occurrence of ADRs) would have 
provided actual safety data. Hence, no assessment of the 
clinical safety of the drug regimens could be made with 
these data, and the drug-risk category indicates potential 
safety risks. Nevertheless, the focus of this study was to 
provide insight into drug prescriptions and potentially inap-
propriate drug utilization in these patients on a large scale. 
A further study using patient charts can examine adher-
ence to the recommendations on a more granular level. In 
Table 2  Period prevalence of the 10 most frequently used drug groups in the first year of follow-up and during total follow-up, with their main 
individual drugs as example
Drug groups are defined as ATC 4th-level subgroups, and individual drugs are defined as ATC 5th-level drugs. Drugs are sorted in descending 
order by the total follow-up prevalence of the drug group
ATC Anatomical Therapeutic Chemical
a Percentages do not round up to 100% because patients can be counted in more than one group
Drug group ATC code First year of follow-up Total follow-up
No. of users Period preva-
lence (%)a
No. of users Period 
prevalence 
(%)a
Proton pump inhibitors A02BC 3030 53.9 3833 68.2
 Pantoprazole A02BC02 1404 25.0 1963 34.9
 Omeprazole A02BC01 1149 20.5 1809 32.2
Sulfonamide diuretics, plain C03CA 2322 41.3 2800 49.8
 Furosemide C03CA01 2001 35.6 2470 44.0
Osmotically acting laxatives A06AD 1832 32.6 2791 49.7
 Lactulose A06AD11 1155 20.6 1661 29.6
 Macrogol, combinations A06AD65 804 14.3 1623 28.9
Aldosterone antagonists C03DA 2451 43.6 2755 49.0
 Spironolactone C03DA01 2428 43.2 2734 48.7
Benzodiazepine derivates, anxiolytics N05BA 1216 21.6 1763 31.4
 Oxazepam N05BA 741 13.2 1121 20.0
Benzodiazepine derivates, hypnotics and sedatives N05CD 1125 20.0 1638 29.2
 Temazepam N05CD07 869 15.5 1302 23.2
Anilides N02BE 906 16.1 1592 28.3
 Paracetamol N02BE01 637 11.3 1199 21.3
Beta-blocking agents, non-selective C07AA 1215 21.6 1465 26.1
 Propranolol C07AA05 1146 20.4 1354 24.1
Combinations of penicillins, incl. beta-lactamase inhibitors J01CR 538 9.6 1416 25.2
 Amoxicillin and enzyme inhibitor J01CR02 538 9.6 1416 25.2
Glucocorticoids H02AB 726 12.9 1413 25.2
 Prednisolone H02AB06 511 9.1 982 17.5
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Table 3  Overview of drug use per safety class and the five most frequently used drugs per class according to Weersink et al. [11]
The total number of users per safety class is calculated for the total follow-up and includes all drugs from that class, not only the top five. 
Patients were only counted once in the total number
ATC Anatomical Therapeutic Chemical
a The drug-risk category indicates potential safety risks
b For drugs evaluated by Weersink et al. [11], total numbers represent the number of evaluated drugs prescribed
c This is one of the top three because only three drugs were part of this class
d Since no data were available about the severity of cirrhosis (Child–Pugh class), these drugs could not be classified further
e For drugs with no safety evaluation as yet, the total is the total number of ATC classes without evaluation
Safety  classa Drug ATC code No. of users Period prevalence dur-
ing total follow-up (%)
Safe Total (n = 27)b 4836 86.1
Spironolactone C03DA01 2734 48.7
Furosemide C03CA01 2470 44.0
Lactulose A06AD11 1661 29.6
Amoxicillin and enzyme inhibitor J01CR02 1416 25.2
Propranolol C07AA05 1354 24.1
No additional risks known Total (n = 50)b 4366 77.7
Macrogol, combinations A06AD65 1623 28.9
Tramadol N02AX02 1091 19.4
Esomeprazole A02BC05 924 16.4
Acetylsalicylic acid B01AC06 789 14.0
Metoclopramide A03FA01 711 12.7
Additional risks known Total (n = 3)b,c 156 2.8
Azathioprine L04AX01 99 1.8
Methadone N07BC02 52 0.9
Heparin B01AB01 6 0.1
Unsafe Total (n = 25)b 3368 60.0
Pantoprazole A02BC02 1963 34.9
Diclofenac M01AB05 1246 22.2
Ibuprofen M01AE01 612 10.9
Naproxen M01AE02 592 10.5
Atorvastatin C10AA05 347 6.2
Unknown Total (n = 27)b 2244 39.9
Doxycycline J01AA02 1080 19.2
Nitrofurantoin J01XE01 622 11.1
Flucloxacillin J01CF05 619 11.0
Magnesium hydroxide A02AA04 240 4.3
Pheneticillin J01CE05 160 2.8
Depending on the severity of 
 cirrhosisd
Total (n = 49)b 3872 68.9
Omeprazole A02BC01 1809 32.2
Codeine R05DA04 908 16.2
Metoprolol C07AB02 872 15.5
Simvastatin C10AA01 846 15.1
Fentanyl N02AB03
N01AH01
594 10.6
Safety not yet evaluated Total (n = 1005)e 5415 96.4
Thiamine (vitamin B1) A11DA01 1374 24.5
Temazepam N05CD07 1302 23.2
Other emollients and protectives D02AX 1236 22.0
Oxazepam N05BA04 1121 20.0
Phytomenadione B02BA01 894 15.9
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addition, more prospective data on clinical outcomes of drug 
use in patients with cirrhosis are needed to determine actual 
safety risk, for example as undertaken by Chalasani et al 
[26]. Important areas to explore are potential drug-related 
complications that were attributed to hospital admission or 
death, such as gastrointestinal bleeding or renal insufficiency 
attributable to NSAIDs, hepatic encephalopathy or sponta-
neous bacterial peritonitis linked to proton pump inhibitors, 
and rhabdomyolysis caused by statins.
How could the prescribing of potentially unsafe drugs 
in cirrhosis be reduced in practice? Several interventions 
have shown to be effective in changing prescribing, such as 
educational outreach visits, audit and feedback and clinical 
decision support [27, 28]. However, specific applications 
in cirrhotic patients seem rare. In The Netherlands, the rec-
ommendations on safe drug use have been incorporated in 
clinical decision support systems used by general practi-
tioners and pharmacists and on a free website [29]. To our 
knowledge, this approach is new for this patient group and 
can possibly serve as an example to implement personalised 
pharmacotherapy in clinical practice.
5  Conclusions
Our study demonstrated that patients with cirrhosis use 
many drugs, with proton pump inhibitors and diuretics being 
the most commonly used drugs. We showed that a large 
number of cirrhotic patients used potentially unsafe drugs, 
which possibly puts them at risk for ADRs due to pharma-
cokinetic or pharmacodynamic changes. Personalised phar-
macotherapy is necessary in these patients to prevent ADRs.
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